“Partnerships in the global biosimilar market evolves a measurable change, thus pushing the market to grow double fold by the end of 2018”, says RNCOS Research.
Noida, UP -- (SBWIRE) -- 06/12/2014 -- Partnerships are evolving rapidly and seem to drive the biosimilar market globally. The big pharmaceutical giants have been aggressively involved in certain agreements for early development of biosimilars soon as and when the product patent expire. Moreover, the companies have been expanding their reach and increasing their market share by the way of collaborations and agreements. For instance, Baxter International and Coherus Biosciences have entered into an exclusive collaboration to develop and commercialize a biosimilar to etanercept for Europe, Canada, Brazil. Besides, Government across the globe have been trying to explore more options for healthcare cost containment.
As per the estimations of our latest report, “Global EPO Biosimilars Market Outlook 2018”, the global biosimilars market backed by the rise of bioclusters in emerging countries will grow at a CAGR of around 50% during 2012-2018. The report contains a thorough study of the EPO biosimilars market, and its future outlook. A basic overview of the total biologics market has been provided, alongwith its current and future size and the trends and drivers which would be responsible for shaping up the market. Some of these factors including rising collaborations among major pharma players and the strong government support to encourage the growth of biosimilars. This is then followed by the total biosimilar market and its future size. The major key segments of the market and their respective shares have also been highlighted.
A brief introduction of the global EPO biosimilar market, its estimated size and its future value has been given. We have also provided a list of the marketed EPO biosimilars and those that are in the pipeline. At the end, key players of the EPO biosimilar market have been profiled where focus has been rested on the business overview, key products and pipeline of the company. Overall, the report aims at providing reliable and complete information about the EPO biosimilar market to clients and potential investors.
For FREE SAMPLE of this report visit: http://www.rncos.com/Report/IM656.htm
Check Related REPORTS on: http://www.rncos.com/Healthcare_Industry.htm
RNCOS is a leading industry research and consultancy firm incorporated in 2002. As a pioneer in syndicate market research, our vision is to be a global leader in the industry research space by providing research reports and actionable insights to companies across a range of industries such as Healthcare, IT and Telecom and Retail etc. We offer comprehensive industry research studies, bespoke research and consultancy services to Fortune 1000, Trade associations, and Government agencies worldwide.